Grann Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Grann Pharmaceuticals is a private, pre-clinical stage biotech leveraging mRNA-LNP technology to address diseases caused by genetic mutations and protein deficiencies. Its pipeline includes programs for obesity/NAFLD, GABA-A variants, Rett syndrome, and colorectal adenocarcinoma, with a core technological focus on engineering LNPs capable of crossing the blood-brain barrier for CNS applications. Founded and led by CEO Thomas Lyle Temple, the company is motivated by a personal legacy and operates as a pre-revenue entity advancing its research toward human trials.

OncologyMetabolic DiseaseRare Genetic DiseaseNeurology

Technology Platform

mRNA lipid nanoparticle (LNP) delivery platform, with a focus on engineering solid lipid nanoparticles (SLNs) under 80nm capable of crossing the blood-brain barrier for CNS applications.

Opportunities

The company's BBB-penetrating LNP technology addresses a major delivery challenge in neurology, opening a large market for CNS genetic disorders.

Additionally, applying its mRNA platform to prevalent metabolic conditions like obesity and NAFLD presents a significant commercial opportunity if clinical efficacy is demonstrated.

Risk Factors

High technical risk in translating its novel LNP platform, especially BBB penetration, from animal models to human efficacy and safety.

The company also faces intense competition in the mRNA therapeutics space from larger, well-capitalized players and is dependent on raising sufficient capital as a pre-revenue entity.

Competitive Landscape

Grann operates in the highly competitive mRNA-LNP field, competing against established players like Moderna, BioNTech, and Arcturus, as well as numerous biotechs focused on rare diseases and CNS delivery. Its differentiation hinges on its specific LNP formulations and claimed BBB penetration capability, which is also being pursued by several other specialized companies.

More companies in mRNA Therapeutics →More companies in United States →